ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
June 14, 2017
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
SGLT2
Diabetes: Mulling Jardiance Heart Benefit
September 30, 2015
The empagliflozin CV benefit was "astounding" and a first for any diabetes drug, but what does it actually mean?
SGLT2 Inhibitors: Mechanism of Action, Pros, and Cons
April 3, 2014
Sodium glucose cotransporter 2 inhibitors act independently of insulin level and so can be used at various stages of type 2 diabetes disease progression. Latest findings, here.
ADA Take-Aways: Assail Obesity, Stay the Course With Incretins
June 26, 2013
Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.
ADA: SGLT2 Inhibitors Match GLP-1 RAs for A1c Reduction, Weight Loss
June 25, 2013
Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.
